<DOC>
	<DOCNO>NCT02222285</DOCNO>
	<brief_summary>The primary study objective evaluate efficacy Vayarin_005 ASD relate symptom child .</brief_summary>
	<brief_title>An Exploratory , Double-Blind , Placebo-Controlled Study Medical Food Vayarin Children With Autism Spectrum Disorder ( ASD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<criteria>1 . Males female , age 617 inclusive 2 . Must valid diagnosis autism spectrum disorder via clinical review DSMIV , confirm Autism Diagnostic Observation Schedule ( ADOS ) 3 . Clinical Global Impression Scale Severity Illness Pervasive Developmental Disorders ( CGISPDD ) rating 4 high ( moderately ill bad ) 4 . IQ &gt; 50 evaluated KBIT2 Stanford Binet Fifth Edition 5 . Able , likely fully comply study procedure instruction 6 . Subjects mood , anxiety , disruptive behavior disorder allow participate study provide meet exclusionary criterion . 7 . Have normal physical examination laboratory test result screen . If abnormal , find ( ) must deem clinically insignificant study Clinician . 8 . Parents legal guardian must able read , write speak English 9 . Parents legal guardian give write informed consent participate study 1 . The subject significantly underweight 5th percentile obese 95th percentile 2 . Clinically significant systemic illness include hepatic , renal , gastroenterological , metabolic , respiratory , cardiovascular ( include ischemic heart disease ) , endocrinologic , neurologic , immunologic , hematologic disease , determine study clinician . 3 . Patients primary psychiatric diagnosis autism screen know genetic syndrome ( ) cause autism . 4 . Suspected establish CNS injury 5 . Change dosage psychiatric pharmacotherapy medication central nervous system effect affect performance 4 week study initiation throughout study phase 6 . Use alphaagonists , ADHD medications 4 week prior study initiation throughout study 7 . Use dietary supplement , 60 day study initiation throughout study 8 . Change educational/behavioral intervention within one month prior participation study 9 . A known comorbid psychiatric diagnose bipolar I disorder , suicidality , substantial psychotic disorder . 10 . Subject participate another clinical trial within 30 day screen trial and/or experimental treatment population 11 . Current history physical , sexual , emotional abuse 12 . History alcohol substance abuse define DSMIV criterion 13 . Consumption &gt; 250 mg/day caffeine 14 . History allergic reaction sensitivity marine product soy 15 . Has illness may jeopardize participant ' health limit successful trial completion . 16 . Any reason , opinion investigator , prevents subject participate study compromise patient safety</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>